COMPASS Pathways plc — Form 8-K
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
COMPASS Pathways reported positive Phase 3 data (COMP006, COMP005) for COMP360 psilocybin in treatment-resistant depression across >1,000 participants. COMP006 (N=581) met primary endpoint (p<0.001) with 25mg dose showing rapid onset (day 2) and durability through 26 weeks; 39% achieved clinically meaningful response at week 6. Safety profile favorable: 94.6% experienced adverse events but majority were transient and on treatment day only; serious adverse events low (5.7% in 25mg arm). Rolling NDA submission and FDA National Priority Voucher already granted; final submission expected Q4 2026; commercial launch targeted H1 2027 with ~578 treatment centers prepared. Market: 4M U.S. TRD patients and 13M PTSD patients identified.
Why this rating
Positive Phase 3 data de-risks FDA approval path and validates commercial strategy for $257M market-cap biotech. Rolling NDA + NPV accelerate timeline materially. Revenue potential substantial if approved, but significant regulatory/reimbursement execution risk remains.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.